Ivabradine tablets 5mg, No. 56

Х Treatment of stable angina pectoris in patients with normal sinus rhythm: with intolerance or contraindications to the use of beta-blockers; in combination with beta-blockers with inadequate control of stable angina pectoris against the background of an optimal dose of beta-blocker Х Chronic heart failure: to reduce the incidence of cardiovascular complications in patients with chronic heart failure, with sinus rhythm and heart rate of at least 70 beats / min.

The average recommended starting dose of ivabradine is 5 mg 2 times / day (10 mg / day). Depending on the therapeutic effect, after 3-4 weeks of use, the dose can be increased to 7.5 mg 2 times / day (15 mg / day). bradycardia (such as dizziness, fatigue, or hypotension), a lower dose should be selected; if necessary, the dose can be reduced to 2.5 mg 2 times / day. If the heart rate remains less than 50 beats / min and the symptoms of bradycardia persist, then treatment is discontinued. In elderly patients, it is recommended to start treatment with an initial dose of 2.5 mg 2 times / day. In the future, it is possible to increase the daily dose depending on the patient's condition.

Film-coated tablets 1 tablet core

active substance:

ivabradine hydrobromide 5.864 / 8.796 mg corresponds to ivabradine - 5 / 7.5 mg

excipients: lactose monohydrate - 64.636 / 96.954 mg; MCC - 20/30 mg; povidone - 6/9 mg; croscarmellose sodium - 2/3 mg; colloidal silicon dioxide - 0.5 / 0.75 mg; magnesium stearate - 1 / 1.5 mg

excipients: Opadry orange 03H325991 (hypromellose - 71.714%, titanium dioxide (E171) - 15.936%, talc - 6.972%, propylene glycol - 4.98%, iron dye yellow oxide (E 172) - 0.332%, iron dye red oxide ( E 172) - 0.066%) - 3 / 4.5 mg

Bradycardia (resting heart rate below 60 beats / min before treatment); cardiogenic shock; acute myocardial infarction; severe arterial hypotension (systolic blood pressure below 90 mm Hg and diastolic blood pressure below 50 mm Hg); severe liver failure (more than 9 points on the Child-Pugh scale); SSSU; sinoatrial blockade; chronic heart failure of III and IV functional class according to NYHA classification; the presence of an artificial pacemaker operating in constant stimulation mode; unstable angina; AV block III degree; pregnancy; lactation period (breastfeeding); children and adolescents up to 18 years old; simultaneous use with strong inhibitors of the CYP3A4 isoenzyme, such as antifungal agents of the azole group (ketoconazole, itraconazole), antibiotics of the macrolide group (clarithromycin,oral erythromycin, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone; hypersensitivity to ivabradine.